JP2015500241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500241A5 JP2015500241A5 JP2014544937A JP2014544937A JP2015500241A5 JP 2015500241 A5 JP2015500241 A5 JP 2015500241A5 JP 2014544937 A JP2014544937 A JP 2014544937A JP 2014544937 A JP2014544937 A JP 2014544937A JP 2015500241 A5 JP2015500241 A5 JP 2015500241A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sustained release
- hours
- active ingredient
- weight percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 76
- 239000008187 granular material Substances 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 28
- 238000013268 sustained release Methods 0.000 claims description 28
- 239000012730 sustained-release form Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 150000003904 phospholipids Chemical class 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 claims description 6
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000001993 wax Substances 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003925 fat Substances 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- -1 fatty alcohol esters Chemical class 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 238000005563 spheronization Methods 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 25
- 239000001506 calcium phosphate Substances 0.000 description 15
- 239000007939 sustained release tablet Substances 0.000 description 15
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 14
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 14
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 14
- 229940038472 dicalcium phosphate Drugs 0.000 description 14
- 235000021355 Stearic acid Nutrition 0.000 description 13
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 13
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 13
- 239000008117 stearic acid Substances 0.000 description 13
- 239000008240 homogeneous mixture Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000001856 Ethyl cellulose Substances 0.000 description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 9
- 235000019325 ethyl cellulose Nutrition 0.000 description 9
- 229920001249 ethyl cellulose Polymers 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 7
- 230000001050 lubricating effect Effects 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 6
- 239000012178 vegetable wax Substances 0.000 description 6
- 235000015278 beef Nutrition 0.000 description 5
- 235000013869 carnauba wax Nutrition 0.000 description 5
- 239000004203 carnauba wax Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 4
- 235000012343 cottonseed oil Nutrition 0.000 description 4
- 239000002385 cottonseed oil Substances 0.000 description 4
- 229940049654 glyceryl behenate Drugs 0.000 description 4
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 3
- 229960002146 guaifenesin Drugs 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566279P | 2011-12-02 | 2011-12-02 | |
| US61/566,279 | 2011-12-02 | ||
| PCT/US2012/067361 WO2013082470A1 (en) | 2011-12-02 | 2012-11-30 | Amphipathic lipid-based sustained release compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015500241A JP2015500241A (ja) | 2015-01-05 |
| JP2015500241A5 true JP2015500241A5 (https=) | 2017-01-26 |
Family
ID=48524178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544937A Pending JP2015500241A (ja) | 2011-12-02 | 2012-11-30 | 両親媒性脂質をベースとする徐放性組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9248096B2 (https=) |
| EP (1) | EP2785333A4 (https=) |
| JP (1) | JP2015500241A (https=) |
| AU (1) | AU2012345726B2 (https=) |
| BR (1) | BR112014013175B1 (https=) |
| CA (1) | CA2854054C (https=) |
| MX (1) | MX351453B (https=) |
| WO (1) | WO2013082470A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017048859A1 (en) * | 2015-09-16 | 2017-03-23 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US20190110988A1 (en) * | 2017-10-17 | 2019-04-18 | Lemulsa Technologies Inc. | Delivery System That Utilizes Liposomal or Emulsion Vehicles |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3886814B1 (en) | 2018-11-26 | 2025-02-19 | The Procter & Gamble Company | Solid pharmaceutical preparation containing lipoic acid and use thereof |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6348226A (ja) * | 1986-08-14 | 1988-02-29 | Ono Pharmaceut Co Ltd | 徐放性を有する経口投与用固形製剤 |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US6077534A (en) * | 1997-09-02 | 2000-06-20 | Klinge Pharma Gmbh | Production of pharmaceutical formulations for treatment of edema and venous disorders |
| DE19740983A1 (de) * | 1997-09-18 | 1999-04-08 | Warner Lambert Co N D Ges D St | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten |
| ES2331442T3 (es) | 1998-03-23 | 2010-01-04 | General Mills, Inc. | Encapsulacion de componentes en productos comestibles. |
| CA2377301C (en) | 1999-06-14 | 2009-05-12 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
| PL204079B1 (pl) * | 2004-08-12 | 2009-12-31 | Inst Farmaceutyczny | Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania |
| ATE476176T1 (de) | 2007-03-02 | 2010-08-15 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
| US8404275B2 (en) | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| CA2736119C (en) * | 2008-09-04 | 2016-08-23 | Farnam Companies, Inc. | Chewable sustained release formulations |
| WO2010136193A1 (en) * | 2009-05-28 | 2010-12-02 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition comprising tamsulosin |
-
2012
- 2012-11-30 JP JP2014544937A patent/JP2015500241A/ja active Pending
- 2012-11-30 EP EP12854388.1A patent/EP2785333A4/en active Pending
- 2012-11-30 CA CA2854054A patent/CA2854054C/en active Active
- 2012-11-30 US US13/690,974 patent/US9248096B2/en active Active
- 2012-11-30 MX MX2014006271A patent/MX351453B/es active IP Right Grant
- 2012-11-30 WO PCT/US2012/067361 patent/WO2013082470A1/en not_active Ceased
- 2012-11-30 AU AU2012345726A patent/AU2012345726B2/en active Active
- 2012-11-30 BR BR112014013175-9A patent/BR112014013175B1/pt active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500241A5 (https=) | ||
| US20210052500A1 (en) | Multiparticulate formulations of cannabinoids | |
| US6375987B1 (en) | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix | |
| JP3449253B2 (ja) | 硬質カプセルの製造方法 | |
| JP6338604B2 (ja) | 獣医学用の経口栄養・医薬組成物 | |
| JP2005538128A (ja) | ペット用のおいしい制御放出処方物 | |
| US6194005B1 (en) | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix | |
| US11110057B2 (en) | Micro particles for oral delivery in animals | |
| EP1809260B1 (en) | Aqueous pharmaceutical coating | |
| JPS5846019A (ja) | 持続性ニフエジピン製剤 | |
| US9737530B1 (en) | Process of making stable abuse-deterrent oral formulations | |
| HUP0100562A2 (hu) | Szferoidok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| JP2017222650A (ja) | 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用 | |
| JP2025060651A (ja) | ビタミンｄ小児用剤形、製造方法および使用方法 | |
| JP2008539230A (ja) | 脂質相を含む薬学的投与形態 | |
| ES2986331T3 (es) | Composiciones sólidas a base de minerales y formulaciones desintegrables oralmente que las contienen | |
| JP2005527207A (ja) | 生理的に認容される、リン脂質を含有する、安定でかつ硬質のマトリックス | |
| CA2877134A1 (en) | Extended-release levetiracetam and method of preparation | |
| CA3054772A1 (en) | Composition for controlled release of physiologically active substances and process for its preparation | |
| EP1952805B1 (en) | Tablet containing hydrogenated phospholipids | |
| US20050271708A1 (en) | Palatable controlled-release formulation for companion animals | |
| ES2954286T3 (es) | Composiciones de piridostigmina de liberación sostenida | |
| US20020142037A1 (en) | Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix | |
| JPH0566365B2 (https=) | ||
| PT89350B (pt) | Processo para a preparacao de uma combinacao sinergistica de inibidores de descarboxilase e de l-dopa e de composicoes farmaceuticas que a contem |